Larimar Therapeutics, Inc. (LRMR)
NasdaqGM · USD · Healthcare · Biotechnology
$2.24 (-4.68%) as of
Key statistics
- Market cap
- 232.70M
- Forward P/E
- -2.11
- EPS (TTM)
- -1.9000
- Dividend yield
- 0.00%
- 52-week range
- 1.9150 – 6.4200
- Beta
- 0.69
- Profit margin
- 0.00%
- Analyst target
- $14.40
- Volume
- 1.31M
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Bala Cynwyd, PA, United States
- Employees
- 71
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.